VJVirtual | T-cell therapy for sarcomas: a promising new approach
Robin Jones, MD, The Royal Marsden Hospital, London, UK, comments on the introduction of adoptive T-cell therapy for synovial sarcoma and its potential for other solid tumors. He highlights that the FDA approval of afami-cel for synovial sarcoma is a significant milestone, and the results of the single-arm trial are very encouraging. Prof. Jones believes that this therapy has opened the door for adoptive T-cell therapies in sarcomas and other solid tumors, and hopes to see more clinical trials in the coming years, promising exciting developments for patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
